Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Frontiers in Cardiovascular Medicine|February 1, 2021
Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement TherapySatoshi Morimoto, Ayumi Nojiri, Eiko Fukuro, et al.
Molecular Genetics and Metabolism|October 5, 2020
Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT studyUlla Feldt-Rasmussen, Derralynn Hughes, Gere Sunder-Plassmann, et al.
Molecular Genetics and Metabolism|May 12, 2018
The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patientsKenichi Hongo, Keiichi Ito, Taro Date, et al.
The Journal of Clinical Investigation|April 8, 2025
AAV expression of a blood-brain barrier-penetrating form of β-galactosidase normalises GM1 ganglioside storage in miceSaki Kondo Matsushima, Yohta Shimada, Masafumi Kinoshita, et al.
American Journal of Human Genetics|October 27, 2009
Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry diseaseYouichi Tajima, Ikuo Kawashima, Takahiro Tsukimura, et al.
Molecular Genetics and Metabolism|March 6, 2010
Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy caseHiroshi Kobayashi, Yohta Shimada, Masahiro Ikegami, et al.
Cancer Science|August 30, 2021
Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cellsTomohiko Taniai, Yoshihiro Shirai, Yohta Shimada, et al.
Pageof 14